Info: Read More
  • 中药标准品生产商,产品定制服务
  • 甘草查尔酮E

    Licochalcone E

    甘草查尔酮E
    产品编号 CFN93297
    CAS编号 864232-34-8
    分子式 = 分子量 C21H22O4 = 338.40
    产品纯度 >=98%
    物理属性 Powder
    化合物类型 Chalcones
    植物来源 The roots of Glycyrrhiza glabra L.
    ChemFaces的产品在影响因子大于5的优秀和顶级科学期刊中被引用
    提供自定义包装
    产品名称 产品编号 CAS编号 包装 QQ客服
    甘草查尔酮E CFN93297 864232-34-8 1mg QQ客服:2159513211
    甘草查尔酮E CFN93297 864232-34-8 5mg QQ客服:2159513211
    甘草查尔酮E CFN93297 864232-34-8 10mg QQ客服:2159513211
    甘草查尔酮E CFN93297 864232-34-8 20mg QQ客服:2159513211
    存储与注意事项
    1. 在您收到产品后请检查产品。如无问题,请将产品存入冰霜并且样品瓶保持密封,产品可以存放长达24个月(2-8摄氏度)。

    2. 只要有可能,产品溶解后,您应该在同一天应用于您的实验。 但是,如果您需要提前做预实验,或者需要全部溶解,我们建议您将溶液以等分试样的形式存放在-20℃的密封小瓶中。 通常,这些可用于长达两周。 使用前,打开样品瓶前,我们建议您将产品平衡至室温至少1小时。

    3. 需要更多关于溶解度,使用和处理的建议? 请发送电子邮件至:service@chemfaces.com
    订购流程
  • 1. 在线订购
  • 请联系我们QQ客服

  • 2. 电话订购
  • 请拨打电话:
    027-84237683 或 027-84237783

  • 3. 邮件或传真订购
  • 发送电子邮件到: manager@chemfaces.com 或
    发送传真到:027-84254680

  • 提供订购信息
  • 为了方便客户的订购,请需要订购ChemFaces产品的客户,在下单的时候请提供下列信息,以供我们快速为您建立发货信息。
  •  
  • 1. 产品编号(CAS No.或产品名称)
  • 2. 发货地址
  • 3. 联系方法 (联系人,电话)
  • 4. 开票抬头 (如果需要发票的客户)
  • 5. 发票地址(发货地址与发票地址不同)
  • 发货时间
    1. 付款方式为100%预付款客户,我们将在确认收到货款后当天或1-3个工作日发货。

    2. 付款方式为月结的客户,我们承诺在收到订单后当天或1-3个工作日内发货。

    3. 如果客户所需要的产品,需要重新生产,我们有权告知客户,交货时间需要延期。
    ChemFaces的产品在许多优秀和顶级科学期刊中被引用

    Cell. 2018 Jan 11;172(1-2):249-261.e12.
    doi: 10.1016/j.cell.2017.12.019.
    IF=36.216(2019)

    PMID: 29328914

    Cell Metab. 2020 Mar 3;31(3):534-548.e5.
    doi: 10.1016/j.cmet.2020.01.002.
    IF=22.415(2019)

    PMID: 32004475

    Mol Cell. 2017 Nov 16;68(4):673-685.e6.
    doi: 10.1016/j.molcel.2017.10.022.
    IF=14.548(2019)

    PMID: 29149595

    ACS Nano. 2018 Apr 24;12(4): 3385-3396.
    doi: 10.1021/acsnano.7b08969.
    IF=13.903(2019)

    PMID: 29553709

    Nature Plants. 2016 Dec 22;3: 16206.
    doi: 10.1038/nplants.2016.205.
    IF=13.297(2019)

    PMID: 28005066

    Sci Adv. 2018 Oct 24;4(10): eaat6994.
    doi: 10.1126/sciadv.aat6994.
    IF=12.804(2019)

    PMID: 30417089
    我们的产品现已经出口到下面的研究机构与大学,并且还在增涨
  • University of Pretoria (South Africa)
  • Wageningen University (Netherlands)
  • University of Stirling (United Kingdom)
  • VIT University (India)
  • Universidade Federal de Santa Catarina (Brazil)
  • Siksha O Anusandhan University (India)
  • Florida International University (USA)
  • University of Madras (India)
  • Chiang Mai University (Thailand)
  • Medizinische Universit?t Wien (Austria)
  • University of Bordeaux (France)
  • University of Maryland (USA)
  • University of Mysore (India)
  • John Innes Centre (United Kingdom)
  • More...
  • 国外学术期刊发表的引用ChemFaces产品的部分文献
  • Exp Biol Med (Maywood).2019, 244(16):1463-1474
  • Curr Issues Mol Biol.2022, 44(10):5106-5116.
  • J Biochem Mol Toxicol.2022, e23211.
  • J Pharmaceut Biomed2020, 182:113110
  • J Korean Med Ophthalmol Otolaryngol Dermatol2023, 36(1):21-39.
  • Exp Parasitol.2015, 153:160-4
  • University of Guelph2021, 12.
  • J Ethnopharmacol.2019, 244:112074
  • Biochem Biophys Res Commun.2017, 494(3-4):587-593
  • Korean Journal of Medicinal Crop Science2018, 26(5):382-390
  • Int. J. of Food Properties2017, S108-S118
  • Enzyme Microb Technol.2022, 153:109941.
  • Heliyon2020, 6(6):e04337.
  • Hindawi J of Food Biochemistry2023, P17:8883860
  • Food Res Int.2022, 157:111207.
  • Carbohydrate Polymer Technologies & App.2021, 2:100049.
  • Saudi Pharmaceutical Journal2023, 31(12):101829
  • J Chromatogr Sci.2015, 53(5):824-9
  • Chinese Medicine2019, 14(1)
  • Sci Rep.2019, 9:19059
  • Natural Product Communications2020, doi: 10.1177.
  • Int J Mol Sci.2022, 23(21):13112.
  • Phytomedicine.2022, 96:153877.
  • ...
  • 生物活性
    Description: Licochalcone E is a potential LXRβ agonist, which has chemopreventive, cytotoxic, anti-inflammatory, antimicrobial, antidiabetic effects; it increases the levels of PPARγ expression, at least in part, via the stimulation of Akt signals and functions as a PPARγ partial agonist. Licochalcone E may be used for the treatment of hepatotoxicity, and primarily exhibits its protective role through a PPARγ/NF-κB-mediated pathway. Licochalcone E is also a potential activator of the Nrf2/ARE-dependent pathway and is therapeutically relevant not only to oxidative-stress-related neurodegeneration but also inflammatory responses of microglial cells both in vitro and in vivo.
    Targets: Liver X Receptor | PPAR | TNF-α | NF-kB | NOS | COX | JNK | ERK | PGE | p38MAPK | IkB | AP-1 | p65 | VEGFR | Bcl-2/Bax | Caspase | MMP(e.g.TIMP) | Nrf2 | IKK
    In vitro:
    Zhongguo Zhong Yao Za Zhi. 2016 Aug;41(16):3065-3071.
    Discovery of potential LXRβ agonists from Chinese herbs using molecular simulation methods.[Pubmed: 28920350]
    Liver X receptor β (LXRβ) has been a new target in the treatment of hyperlipemia, which was related to the cholesterol homeostasis.
    METHODS AND RESULTS:
    In this study, the quantitative pharmacophores were constructed by 3D-QSAR pharmacophore (Hypogen) method based on the LXRβ agonists. The optimal pharmacophore model containing one hydrogen bond acceptor, two hydrophobics and one ring aromatic was obtained based on five assessment indictors, including the correlation between predicted value and experimental value of the compounds in training set (correlation), Δcost of the models (Δcost), hit rate of active compounds (HRA), identification of effectiveness index (IEI) and comprehensive evaluation index (CAI). And the values of the five assessment indicators were 0.95, 128.65, 84.44%, 2.58 and 2.18 respectively. The best model as a query to screen the traditional Chinese medicine database (TCMD), a list of 309 compounds was obtained andwere then refined using Libdock program. Finally, based on the screening rules of the Libdock score of initial compound and the key interactions between initial compound and receptor, four compounds, demethoxycurcumin, isolicoflavonol, Licochalcone E and silydianin, were selected as potential LXRβ agonists.
    CONCLUSIONS:
    The molecular simulation methods were high-efficiency and time-saving to obtainthe potential LXRβ agonists, which could provide assistance for further researchingnovel anti-hyperlipidemia drugs.
    J Microbiol Biotechnol. 2012 Jun;22(6):800-5.
    Antimicrobial activity of licochalcone E against Staphylococcus aureus and its impact on the production of staphylococcal alpha-toxin.[Pubmed: 22573157]
    Licochalcone E was firstly isolated from licorice root in 2005, which belongs to the retrochalcone family. Studies on the biological activities of Licochalcone E were in the initial stage.
    METHODS AND RESULTS:
    In the study, we demonstrated that Licochalcone E has potent antimicrobial property against Staphylococcus aureus. Furthermore, via hemolysis, Western blot, and real-time RT-PCR assays, we have shown that subinhibitory concentrations of Licochalcone E dosedependently reduces the production of alpha-toxin in both methicillin-sensitive S. aureus (MSSA) and methicillinresistant S. aureus (MRSA).
    CONCLUSIONS:
    The data suggest that Licochalcone E may deserve further investigation as a potential therapeutic against S. aureus infections, or the structure of Licochalcone E may be used as a basis for chemical synthesis of novel anti-S. aureus compounds.
    J Nutr Biochem. 2012 Jul;23(7):759-67.
    Licochalcone E has an antidiabetic effect.[Pubmed: 21840191]
    Licochalcone E (lico E) is a retrochalcone isolated from the root of Glycyrrhiza inflata. Retrochalcone compounds evidence a variety of pharmacological profiles, including anticancer, antiparasitic, antibacterial, antioxidative and superoxide-scavenging properties.
    METHODS AND RESULTS:
    In this study, we evaluated the biological effects of lico E on adipocyte differentiation in vitro and obesity-related diabetes in vivo. We employed 3T3-L1 preadipocyte and C3H10T1/2 stem cells for in vitro adipocyte differentiation study and diet-induced diabetic mice for in vivo study. The presence of lico E during adipogenesis induced adipocyte differentiation to a significant degree, particularly at the early induction stage. Licochalcone E evidenced weak, but significant, peroxisome proliferator-activated receptor gamma (PPARγ) ligand-binding activity. Two weeks of lico E treatment lowered blood glucose levels and serum triglyceride levels in the diabetic mice. Additionally, treatment with lico E resulted in marked reductions in adipocyte size and increases in the mRNA expression levels of PPARγ in white adipose tissue (WAT). Licochalcone E was also shown to significantly stimulate Akt signaling in epididymal WAT.
    CONCLUSIONS:
    In conclusion, lico E increases the levels of PPARγ expression, at least in part, via the stimulation of Akt signals and functions as a PPARγ partial agonist, and this increased PPARγ expression enhances adipocyte differentiation and increases the population of small adipocytes, resulting in improvements in hyperglycemia and hyperlipidemia under diabetic conditions.
    Int Immunopharmacol. 2010 Sep;10(9):1119-26.
    Licochalcone E reduces chronic allergic contact dermatitis and inhibits IL-12p40 production through down-regulation of NF-kappa B.[Pubmed: 20601178 ]
    Licochalcone, a constituent of licorice, has antitumor, antimicrobial, and anti-inflammatory effects. Recently, Licochalcone E was isolated from the roots of Glycyrrhiza inflata and its biological functions are not fully examined.
    METHODS AND RESULTS:
    In this study, we investigated its ability to modulate production of IL-12p40, a common subunit of IL-12 and IL-23. Licochalcone E dose-dependently inhibited IL-12p40 production from lipopolysaccharide-stimulated RAW264.7 macrophage cells. The repressive effect was mapped to a region in the IL-12 gene promoter containing a binding site for NF-kappaB. Furthermore, Licochalcone E decreased binding to the NF-kappaB site in RAW264.7 macrophage cells. Using a chronic allergic contact dermatitis model induced by repeated application of oxazolone, we showed that Licochalcone E inhibited the increased IL-12p40 expression and ear thickness induced by oxazolone.
    CONCLUSIONS:
    Taken together, Licochalcone E inhibits IL-12p40 production and has therapeutic potential to reduce skin inflammation.
    In vivo:
    Cancer Prev Res (Phila). 2013 Jun;6(6):603-13.
    Licochalcone E present in licorice suppresses lung metastasis in the 4T1 mammary orthotopic cancer model.[Pubmed: 23625311]
    We investigated whether Licochalcone E (LicE), a phenolic constituent of licorice, inhibits mammary tumor growth and metastasis using animal and cell culture models.
    METHODS AND RESULTS:
    4T1 mammary carcinoma cells were injected into the mammary fat pads of syngeneic BALB/c mice. Starting 7 days after the injection, the mice received LicE (7 or 14 mg/kg body weight/day) via oral gavage for 25 days. LicE suppressed solid tumor growth and lung metastasis, but did not exhibit kidney or liver toxicity. In tumor tissues, LicE treatment induced a reduction in the expression of Ki67, cyclins, and cyclin-dependent kinases and stimulated apoptosis with increased expression of Bax and cleaved caspase-3 but decreased expression of Bcl-2. In addition, LicE decreased expression of CD31, vascular endothelial growth factor (VEGF)-A and C, VEGF-receptor 2, lymphatic vessel endothelial receptor-1, CD45, cyclooxygenase-2, inducible nitric oxide synthase, and hypoxia inducible factor-1α in tumor tissues. In lung tissues, LicE reduced the levels of proinflammatory cytokines and angiogenesis/metastasis-related proteins. In mammary cancer cell cultures, LicE (5-20 μmol/L) dose dependently inhibited cell migration and invasion. LicE inhibited secretion of matrix metalloproteinase-9, urokinase-type plasminogen activator and VEGF-A, and stimulated secretion of tissue inhibitor of metalloproteinase-2 in MDA-MB-231 cells. In addition, LicE inhibited tube formation of vascular endothelial cells.
    CONCLUSIONS:
    We show that LicE administration suppressed tumor growth and lung metastasis in the mouse model in conjunction with LicE inhibition of cell migration, invasion, and tube formation in vitro. Reduced tumor growth and metastasis in LicE-treated mice may be, at least in part, attributed to reduced inflammation and tumor angiogenesis.
    制备储备液(仅供参考)
    1 mg 5 mg 10 mg 20 mg 25 mg
    1 mM 2.9551 mL 14.7754 mL 29.5508 mL 59.1017 mL 73.8771 mL
    5 mM 0.591 mL 2.9551 mL 5.9102 mL 11.8203 mL 14.7754 mL
    10 mM 0.2955 mL 1.4775 mL 2.9551 mL 5.9102 mL 7.3877 mL
    50 mM 0.0591 mL 0.2955 mL 0.591 mL 1.182 mL 1.4775 mL
    100 mM 0.0296 mL 0.1478 mL 0.2955 mL 0.591 mL 0.7388 mL
    * Note: If you are in the process of experiment, it's need to make the dilution ratios of the samples. The dilution data of the sheet for your reference. Normally, it's can get a better solubility within lower of Concentrations.
    部分图片展示
    产品名称 产品编号 CAS编号 分子式 = 分子量 位单 联系QQ
    Pterocarpadiol B; Pterocarpadiol B CFN89481 2055882-20-5 C16H14O6 = 302.27 5mg QQ客服:1413575084
    三七皂苷Fa; Notoginsenoside Fa CFN93284 88100-04-3 C59H100O27 = 1241.4 20mg QQ客服:1457312923
    五水棉子糖; Raffinose CFN90425 17629-30-0 C18H32O16(5H2O) = 594.51 20mg QQ客服:215959384
    药根碱; Jatrorrhizine CFN98493 3621-38-3 C20H20NO4 = 338.4 20mg QQ客服:215959384

    信息支持


    公司简介
    订购流程
    付款方式
    退换货政策

    ChemFaces提供的产品仅用于科学研究使用,不用于诊断或治疗程序。

    联系方式


    电机:027-84237783
    传真:027-84254680
    在线QQ: 1413575084
    E-Mail:manager@chemfaces.com

    湖北省武汉沌口经济技术开区车城南路83号1号楼第三层厂房


    ChemFaces为科学家,科研人员与企业提供快速的产品递送。我们通过瑞士SGS ISO 9001:2008质量体系认证天然化合物与对照品的研发和生产